Spark Therapeutics Inc (NASDAQ:ONCE) – Investment analysts at SunTrust Banks issued their FY2022 earnings per share (EPS) estimates for shares of Spark Therapeutics in a note issued to investors on Wednesday. SunTrust Banks analyst E. Nash expects that the biotechnology company will post earnings of $7.91 per share for the year. SunTrust Banks has a “Buy” rating and a $113.00 price target on the stock.
Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same period in the previous year, the firm earned ($1.07) earnings per share. The company’s revenue for the quarter was up 45.8% compared to the same quarter last year.
Spark Therapeutics (NASDAQ:ONCE) opened at $50.56 on Friday. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Spark Therapeutics by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after purchasing an additional 96,803 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares during the last quarter. Janus Henderson Group PLC raised its stake in Spark Therapeutics by 46.4% during the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after acquiring an additional 239,723 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in Spark Therapeutics during the 3rd quarter valued at approximately $38,340,000. 94.91% of the stock is owned by institutional investors and hedge funds.
In other news, insider Barge Joseph La sold 3,309 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $71.31, for a total value of $235,964.79. Following the completion of the sale, the insider now directly owns 8,146 shares of the company’s stock, valued at approximately $580,891.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at $15,333,800. The disclosure for this sale can be found here. Insiders sold a total of 62,309 shares of company stock valued at $4,621,085 over the last three months. Company insiders own 7.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “SunTrust Banks Weighs in on Spark Therapeutics Inc’s FY2022 Earnings (ONCE)” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/07/suntrust-banks-weighs-in-on-spark-therapeutics-incs-fy2022-earnings-once.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
What are top analysts saying about Spark Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics and related companies.